Organovo Holdings Inc (ONVO)

Form 8-K - Current report

VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company”) announced that it has emerged from stealth mode...

Form 8-K - Current report

VivoSim to Carry Forward Organovo 3D Bioprinting

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (the “Company”...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements

SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo” or the...

Organovo Provides Business Update

SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the...

Form 8-K - Current report

Form 8-K - Current report

Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company

SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the...

Form 8-K - Current report

Form 8-K - Current report

Organovo Announces Reverse Stock Split

SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage...

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB...